Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis
Emily Edson‐Heredia, K.L. Sterling, Carlos Alatorre, et al.
Journal of Investigative Dermatology (2013) Vol. 134, Iss. 1, pp. 18-23
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

The role of the gut microbiome in systemic inflammatory disease
José C. Clemente, Julia Manasson, Jose U. Scher
BMJ (2018), pp. j5145-j5145
Open Access | Times Cited: 487
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren, Catherine Smith, Z.Z.N. Yiu, et al.
Journal of Investigative Dermatology (2015) Vol. 135, Iss. 11, pp. 2632-2640
Open Access | Times Cited: 343
Critical role of environmental factors in the pathogenesis of psoriasis
Jinrong Zeng, Shuaihantian Luo, Yumeng Huang, et al.
The Journal of Dermatology (2017) Vol. 44, Iss. 8, pp. 863-872
Open Access | Times Cited: 197
Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility
Xianyong Yin, Hui Qi Low, Ling Wang, et al.
Nature Communications (2015) Vol. 6, Iss. 1
Open Access | Times Cited: 181
The gut microbiome in psoriasis and psoriatic arthritis
Bridget Myers, Nicholas Brownstone, Vidhatha Reddy, et al.
Best Practice & Research Clinical Rheumatology (2019) Vol. 33, Iss. 6, pp. 101494-101494
Closed Access | Times Cited: 115
Diet and psoriasis, part I: Impact of weight loss interventions
Maya Debbaneh, Jillian Wong Millsop, Bhavnit K. Bhatia, et al.
Journal of the American Academy of Dermatology (2014) Vol. 71, Iss. 1, pp. 133-140
Open Access | Times Cited: 108
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
Richard B. Warren, Antonia Marsden, Barbara Tomenson, et al.
British Journal of Dermatology (2018) Vol. 180, Iss. 5, pp. 1069-1076
Open Access | Times Cited: 94
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
S.P. Menting, Emma Coussens, Mieke F. Pouw, et al.
JAMA Dermatology (2015) Vol. 151, Iss. 6, pp. 616-616
Open Access | Times Cited: 84
Secukinumab efficacy and safety in Japanese patients with moderate‐to‐severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo‐controlled, phase 3 study
Mamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, et al.
The Journal of Dermatology (2014) Vol. 41, Iss. 12, pp. 1039-1046
Closed Access | Times Cited: 83
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
Kim Papp, Ken Gordon, Richard Langley, et al.
British Journal of Dermatology (2018)
Closed Access | Times Cited: 57
Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
Alice B. Gottlieb, J.‐P. Lacour, Neil J. Korman, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 31, Iss. 4, pp. 679-685
Open Access | Times Cited: 52
Review of Clinical Pharmacology ofAloe veraL. in the Treatment of Psoriasis
Marco Miroddi, Michele Navarra, Fabrizio Calapai, et al.
Phytotherapy Research (2015) Vol. 29, Iss. 5, pp. 648-655
Closed Access | Times Cited: 47
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals
Jenny M. Norlin, Kristoffer Nilsson, Ulf Persson, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 4, pp. 965-973
Open Access | Times Cited: 36
Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
Yi‐Teng Hung, Yu‐Jr Lin, Hsien‐Yi Chiu, et al.
Therapeutic Advances in Chronic Disease (2021) Vol. 12
Open Access | Times Cited: 30
Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Dimitrios Rigopoulos, Eleftheria Tampouratzi, Charalampos Angelakopoulos, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 6, pp. 1121-1130
Closed Access | Times Cited: 4
Factors affecting response to biologic treatment in psoriasis
Jacek Karczewski, Barbara Poniedziałek, Piotr Rzymski, et al.
Dermatologic Therapy (2014) Vol. 27, Iss. 6, pp. 323-330
Closed Access | Times Cited: 36
Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
Emanuele Scala, Matteo Megna, Paolo Amerio, et al.
PLoS ONE (2020) Vol. 15, Iss. 8, pp. e0237267-e0237267
Open Access | Times Cited: 32
Long‐term efficacy and safety of infliximab maintenance therapy in patients with plaque‐type psoriasis in real‐world practice
Neil H. Shear, Morghan Hartmann, Mirna Toledo‐Bahena, et al.
British Journal of Dermatology (2014) Vol. 171, Iss. 3, pp. 631-641
Closed Access | Times Cited: 33
Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study
Nan‐Lin Wu, Chih‐Jung Hsu, Fang‐Ju Sun, et al.
The Journal of Dermatology (2017) Vol. 44, Iss. 10, pp. 1129-1137
Closed Access | Times Cited: 33
Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study
Teodora-Larisa Timiș, Lehel Beni, Ioan Alexandru Florian, et al.
Medicine and Pharmacy Reports (2023) Vol. 96, Iss. 4, pp. 368-383
Open Access | Times Cited: 9
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine
Charalabos Antonatos, Paschalia Asmenoudi, Mariza Panoutsopoulou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7090-7090
Open Access | Times Cited: 8
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Alan Kivitz, Joel M. Kremer, Clarence W. Legerton, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 675-689
Open Access | Times Cited: 3
Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study
Clara De Simone, Giacomo Caldarola, Alessia Maiorino, et al.
Dermatologic Therapy (2016) Vol. 29, Iss. 5, pp. 372-376
Open Access | Times Cited: 24
Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults
Marieke E.C. van Winden, L. S. van der Schoot, Mariluz van de L’Isle Arias, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 11, pp. 1229-1229
Closed Access | Times Cited: 22
The influence of body weight of patients with chronic plaque psoriasis on biological treatment response
Anna Kisielnicka, Aneta Szczerkowska‐Dobosz, Roman Nowicki
Advances in Dermatology and Allergology (2020) Vol. 37, Iss. 2, pp. 168-173
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top